COCH · Envoy Medical, Inc. · Documents
$6.51
+0.01 (+0.15%)
At close · Oct 27
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Since inception, the Company has historically incurred negative operating cash flows and losses from operations as the Company advances the clinical development of its products and the funding process of clinical FDA trials. These matters raise substantial doubt about the Company's ability to continue as a going concern and although management has developed plans intended to support ongoing operations, such plans do not alleviate the substantial doubt.”View the 10-Q filed Aug 10, 2026
Market Cap
$50.25M
Shares
7.72M
Volume · Oct 27
40.46K
Avg daily vol (2 sessions)
45.15K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Envoy Medical effected a 1-for-10 reverse stock split of its Class A common stock at 12:01 a.m. Eastern Time on October 26, 2026; shares began post-split trading on Nasdaq under “COCH,” with warrants and equity awards proportionately adjusted. | 2026-10-27 | 2026-10-23 | |
| 8-K | Envoy Medical, Inc. said its stockholders at the October 12, 2026 Special Meeting approved giving the Board discretion to effect reverse stock splits of Class A Common Stock at ratios from 1-for-5 to 1-for-25 through December 31, 2026. | 2026-10-16 | 2026-10-12 | |
| 8-K | Envoy Medical, Inc. entered a Dismissal Agreement on October 6, 2026 with Atlas Merchant Capital SPAC Fund I LP, dismissing all litigation claims with prejudice and requiring no payment to Atlas. | 2026-10-07 | 2026-10-06 | |
| DEFA14A | — | 2026-09-02 | — | |
| DEF 14A | — | 2026-08-31 | 2026-10-12 | |
| 8-K | — | 2026-08-27 | 2026-08-24 | |
| PRE 14A | — | 2026-08-19 | — | |
| 10-Q | — | 2026-08-10 | 2026-06-30 | |
| 8-K | — | 2026-08-10 | — | |
| 8-K | — | 2026-06-30 | 2026-06-24 | |
| 8-K | — | 2026-06-25 | 2026-06-19 | |
| Investor Event Transcript | — | 2026-06-17 | 2026-06-30 | |
| 8-K | — | 2026-05-22 | 2026-05-19 | |
| 8-K | — | 2026-05-18 | 2026-05-12 | |
| 10-Q | — | 2026-05-11 | 2026-03-31 | |
| 8-K | — | 2026-05-11 | — | |
| 8-K | — | 2026-04-21 | 2026-04-15 | |
| 10-K/A | — | 2026-04-13 | 2025-12-31 | |
| ARS | — | 2026-04-02 | 2025-12-31 | |
| DEF 14A | — | 2026-04-02 | 2026-05-12 | |
| DEFA14A | — | 2026-04-02 | — | |
| 8-K | — | 2026-03-31 | 2026-03-25 | |
| 8-K | — | 2026-03-27 | 2026-03-23 | |
| 10-K | — | 2026-03-23 | 2025-12-31 | |
| PRE 14A | — | 2026-03-23 | — | |
| 8-K | — | 2026-02-27 | 2026-02-23 | |
| 8-K | — | 2026-02-13 | 2026-02-11 | |
| 8-K | — | 2026-02-11 | 2026-02-05 | |
| S-1/A | — | 2026-02-10 | — | |
| S-1/A | — | 2026-02-06 | — | |
| 8-K | — | 2025-12-29 | 2025-12-18 | |
| S-1 | — | 2025-12-18 | — | |
| 8-K | — | 2025-12-16 | — | |
| 8-K | — | 2025-12-03 | 2025-11-26 | |
| S-1/A | — | 2025-12-01 | — | |
| 8-K | — | 2025-11-25 | 2025-11-19 | |
| 8-K | — | 2025-11-10 | — | |
| 10-Q | — | 2025-11-10 | 2025-09-30 | |
| 8-K | — | 2025-10-28 | 2025-10-23 | |
| DEF 14A | — | 2025-10-17 | 2025-11-26 | |
| S-1 | — | 2025-10-17 | — | |
| 8-K | — | 2025-10-09 | 2025-10-07 | |
| 8-K | — | 2025-10-07 | — | |
| PRE 14A | — | 2025-10-07 | — | |
| 8-K | — | 2025-09-23 | 2025-09-22 | |
| 8-K | — | 2025-09-19 | — | |
| 8-K | — | 2025-09-09 | 2025-09-04 | |
| 8-K | — | 2025-08-29 | 2025-08-26 | |
| 8-K | — | 2025-08-26 | 2025-08-25 | |
| 8-K | — | 2025-07-31 | — |
Showing 1–50 of 158 filings